Ergomed

www.ergomedplc.com TICKER: ERGO     EXCHANGE: AIM

Ergomed offers clinical trial and pharmacovigilance services to pharmaceutical companies, while also co-developing a product portfolio of therapies.

LATEST REPORTS

 
Well-positioned ahead of PeproStat data
Published: Oct 20 2017

Ergomed offers clinical trial and pharmacovigilance services to pharmaceutical companies, while also co-developing a product portfolio of therapies.Ahead of the PeproStat data expected toward the end of this month, Ergomed recently improved its competitive position for its Services businesses with its acquisition of PSR in the Orphan Drug/Rare Disease. At the same time, it signed its first deal for PeproStat (and ReadyFlow), suggesting attractive commercialisation opportunities awaiting the data at the end of the month. Excitingly, the first commercial deal for a Haemsotatix product, Pepr

REGISTER / LOGIN TO VIEW THIS RESEARCH IN FULL

 
Ergomed interim results webinar September 2017
Published: Sep 19 2017

Dr Dan Weng, CEO, Stephen Stamp, CFO and Andrew Mackie, CBO run through the firm's interim results.

REGISTER / LOGIN TO VIEW THIS RESEARCH IN FULL

 
Outlook focused on PeproStat data soon
Published: Sep 18 2017

Ergomed offers clinical trial and pharmacovigilance services to pharmaceutical companies, while also co-developing a product portfolio of therapies.Performance in H1 was in line with expectations as total revenues were up a healthy 31% to £22.9m. While net revenues (excluding reimbursed costs) were up 53% to £19.5m,; good performance was seen across the group. As expected following a £1m increase in R&D spend this year on Haemostatix, EBITDA remained broadly flat year-on-year. Most importantly, the forward order book for the Services businesses remains attractive, standing at £70m at the e

REGISTER / LOGIN TO VIEW THIS RESEARCH IN FULL

 
Ongoing strength in Ergomed's approach
Published: May 08 2017

Ergomed offers clinical trial and pharmacovigilance services to pharmaceutical companies, while also co-developing a product portfolio of therapies.Aeterna Zentaris, a co-development partner of Ergomed, announced that its Pivotal Phase III Clinical Trial of Zoptrex in women with endometrial cancer failed to meet its primary endpoint. As a result, there is no longer any potential upside from the relationship. We have reduced the top end of our valuation range/share which includes the co-development deals, by 39.7p.  While it is disappointing that the phase III trial of Zoptrex failed, it i

REGISTER / LOGIN TO VIEW THIS RESEARCH IN FULL

 
£70m contracted revenues still to come
Published: Apr 11 2017

Ergomed offers clinical trial and pharmacovigilance services to pharmaceutical companies, while also co-developing a product portfolio of therapies.2016 perfectly highlighted the strengths of the Ergomed business: the visibility of its Contracted Revenues and the potential upside from co-development deals. Contracted revenues now stand at an impressive £70m, up from £42m, and the outlook remains auspicious.  FY2016 came in ahead of revised forecasts and there are upgrades to FY2017 onwards. Our FY2016 assumptions were upgraded following the period-end update to revenues of £38m, £2.1m of

REGISTER / LOGIN TO VIEW THIS RESEARCH IN FULL

 
View the Results Webinar
Published: Apr 04 2017

You can now hear Dr. Miroslav Reljanovic, Founder and Chief Executive Officer, Stephen Stamp, Chief Finance Officer, and Andrew Mackie, Chief Business Officer, present the preliminary 2016 results on behalf of Ergomed.To view simply click on the video below. 

REGISTER / LOGIN TO VIEW THIS RESEARCH IN FULL

 
Ergomed plc - Equity Development Investor Forum, January 2017
Published: Jan 27 2017

Stephen Stamp, Chief Financial Officer, presents the exciting opportunities for Ergomed plc.

REGISTER / LOGIN TO VIEW THIS RESEARCH IN FULL

ARCHIVE

2017
2016 revenues ahead of forecasts
Published: Jan 25 2017

Ergomed offers clinical trial and pharmacovigilance services to pharmaceutical companies, while also co-developing a product portfolio of therapies.The recent period end update for Ergomed confirmed the good performance for that was expected for FY2016, with revenues of £38m up 26% year on year, against £35.5m forecast. The company retains its momentum, and with an attractive forward order book currently worth £42m, this could be expected to continue.  Our FY2016 assumptions have been adjusted to reflect the better than expected performance: revenues have increased to &p

REGISTER / LOGIN TO VIEW THIS RESEARCH IN FULL

2016
Adding earnings. Adding future upside.
Published: Dec 13 2016

Ergomed offers clinical trial and pharmacovigilance services to pharmaceutical companies, while also co-developing a product portfolio of therapies. It has unusually high revenue visibility, indeed the order backlog stood at c £60m at the end of July.  The security of revenues is due to two factors: long-term clinical trial contracts in the Clinical Research Organisation (CRO) business and the high client retention rates seen in the Primevigilance business.The recent acquisition of PharmInvent Services adds further high growth revenue stream to Ergomed's portfolio. At the interim results, ma

REGISTER / LOGIN TO VIEW THIS RESEARCH IN FULL

Excellent H1 progress, confident for H2
Published: Oct 11 2016

Ergomed offers clinical trial and pharmacovigilance services to pharmaceutical companies, while also co-developing a product portfolio of therapies. It has unusually high revenue visibility, indeed the order backlog stood at c £60m at the end of July.  The security of revenues is due to two factors: long-term clinical trial contracts in the Clinical Research Organisation (CRO) business and the high client retention rates seen in the Primevigilance business.In an area that is normally fraught with risk, Ergomed has pursued a low risk strategy to benefit from drug development. It prov

REGISTER / LOGIN TO VIEW THIS RESEARCH IN FULL

View the Results Webinar
Published: Sep 30 2016

You can now hear Dr. Miroslav Reljanovic, Founder and Chief Executive Officer, Steven Stamp, Chief Finance Officer, and Andrew Mackie, Chief Business Officer, present the interim results for Ergomed and answer investor questions.To view simply click on the video below.

REGISTER / LOGIN TO VIEW THIS RESEARCH IN FULL